About: Dalfampridine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dalfampridine Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4DA2-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4DA3-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Panitch H, Applebee A: Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability. Expert Opin Pharmacother. 2011 Jul;12(10):1511-21. doi: 10.1517/14656566.2011.586338. Epub 2011 Jun 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21635193 # Pikoulas TE, Fuller MA: Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1010-5. doi: 10.1345/aph.1Q714. Epub 2012 Jul 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22764324 # Cornblath DR, Bienen EJ, Blight AR: The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. Clin Ther. 2012 May;34(5):1056-69. doi: 10.1016/j.clinthera.2012.03.007. Epub 2012 Apr 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22497693 # McDonald S, Clements JN: Dalfampridine: a new agent for symptomatic management of multiple sclerosis. Am J Health Syst Pharm. 2011 Dec 15;68(24):2335-40. doi: 10.2146/ajhp110134. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22135060 # Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16472864 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Immediate release form = 3.5 hours; Extended release form = 5.47 hours; (en)
http://linked.open...ugbank/indication	Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS). (en)
sameAs	Dalfampridine
Title	Dalfampridine (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB06637/identifier/chebi/34385 http://linked.opendata.cz/resource/drugbank/drug/DB06637/identifier/drugbank/DB06637 http://linked.opendata.cz/resource/drugbank/drug/DB06637/identifier/kegg-compound/C13728 http://linked.opendata.cz/resource/drugbank/drug/DB06637/identifier/kegg-drug/D04127 http://linked.opendata.cz/resource/drugbank/drug/DB06637/identifier/national-drug-code-directory/10144-427-60 http://linked.opendata.cz/resource/drugbank/drug/DB06637/identifier/wikipedia/4-Aminopyridine
http://linked.open...mechanismOfAction	In MS, axons are progressively demyelinated which exposes potassium channels. As a result, there is a leak of potassium ions which results in the repolarization of cells and a decrease in neuronal excitability. The overall impact is the impairment of neuromuscular transmission as it is harder to trigger an action potential. Dalfampridine inhibits voltage-gated potassium channels in the CNS to maintain the transmembrane potential and prolong action potential. In other words, dalfampridine works to make sure that the current available is high enough to stimulate conduction in demyelinated axons that are exposed in MS patients. Furthermore, it facilitates neuromuscular and synaptic transmission by relieving conduction blocks in demyelinated axons. (en)
http://linked.open...outeOfElimination	Almost all of the dose and its metabolites are completely eliminated by the kidneys after 24 hours. Urine (96%; 90% of total dose as unchanged drug); Feces (0.5%) (en)
http://linked.open.../drugbank/synonym	Fampridine (en) Dalfampridine (en) 4-Aminopyridine (en) 4-Pyridinamine (en) 4-AP (en) 4-Pyridylamine (en) Ampyra (en) Avitrol (en) EL-970 (en) Fampridina (en) Fampridine-SR (en) Fampridinum (en) N07XX07 (en) P-Aminopyridine (en) gamma-Aminopyridine (en)
http://linked.open...drugbank/toxicity	LD50, oral, mouse = 19 mg/kg LD50, oral, rat = 21 mg/kg (en)
http://linked.open...umeOfDistribution	10 mg extended release = 2.6 L/kg (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/92-92
http://linked.open...k/foodInteraction	A high fat meal significantly increases Cmax but this effect is not clinically relevant. May take dalfampridine without regard to meals (en)
http://linked.open...nk/proteinBinding	10 mg extended release = 1-3% protein bound (en)
http://linked.open...ynthesisReference	Fabio GARAVAGLIA, Alessandro BAROZZA, Jacopo ROLETTO, Paolo PAISSONI, "ONE-POT PROCESS FOR THE SYNTHESIS OF DALFAMPRIDINE." U.S. Patent US20110319628, issued December 29, 2011. (en)
foaf:page	http://www.drugs.com/ampyra.html http://www.rxlist.com/ampyra-drug.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4DA8-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B4DAE-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4DAD-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4DAA-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4DAB-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B4DAC-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B4DA6-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4DBE-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4DA4-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4DA7-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B4DA5-363D-11E5-9242-09173F13E4C5
http://linked.open...logy/drugbank/pKa	http://linked.opendata.cz/resource/drugbank/property/271B4DC1-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Fampridine
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4DB4-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4DB5-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B4DAF-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4DB0-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4DB2-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4DB1-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4DB3-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Orally-administered dalfampridine is rapidly and completely absorbed from the gastrointestinal tract. Tmax, immediate release form = 1 hour; Tmax, extended release form = 3.5 hours; Cmax, 10 mg extended release = 17.3 - 21.6 ng/mL; Relative bioavailability of 10 mg extended-release tablets compared to aqueous oral solution = 96% (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	504-24-5 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B4DBA-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Boiling-Point	http://linked.opendata.cz/resource/drugbank/property/271B4DC0-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B4DBC-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B4DBD-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B4DBF-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B4DB9-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B4DB8-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B4DBB-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4DA9-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B4DB6-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B4DB7-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software